{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lupus&page=11",
    "query": {
      "condition": "Lupus",
      "page": 11
    },
    "page_size": 10
  },
  "pagination": {
    "page": 11,
    "page_size": 10,
    "total_count": 623,
    "total_pages": 63,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lupus&page=12&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lupus&page=10&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-21T12:24:10.625Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05138133",
      "title": "Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lupus Nephritis"
      ],
      "interventions": [
        {
          "name": "Anifrolumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 363,
      "start_date": "2022-02-15",
      "completion_date": "2028-10-04",
      "has_results": false,
      "last_update_posted_date": "2026-07-31",
      "last_synced_at": "2026-10-21T12:24:10.625Z",
      "location_count": 16,
      "location_summary": "Glendale, Arizona • La Palma, California • Los Angeles, California + 13 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "La Palma",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Upland",
          "state": "California"
        },
        {
          "city": "Plantation",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05138133"
    },
    {
      "nct_id": "NCT07611214",
      "title": "PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Lupus Nephritis"
      ],
      "interventions": [
        {
          "name": "LUPKYNIS",
          "type": "DRUG"
        },
        {
          "name": "belimumab, obinutuzumab or anifrolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "mycophenolic acid analog (MPAA)",
          "type": "DRUG"
        },
        {
          "name": "corticosteroid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Aurinia Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 150,
      "start_date": "2026-04-22",
      "completion_date": "2029-03-02",
      "has_results": false,
      "last_update_posted_date": "2026-08-03",
      "last_synced_at": "2026-10-21T12:24:10.625Z",
      "location_count": 27,
      "location_summary": "La Mesa, California • Los Alamitos, California • Arvada, Colorado + 23 more",
      "locations": [
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Los Alamitos",
          "state": "California"
        },
        {
          "city": "Arvada",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Kissimmee",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07611214"
    },
    {
      "nct_id": "NCT00684255",
      "title": "Reduced Intensity Transplant in Medically Refractory Systemic Lupus Erythematosus (SLE) and Systemic Sclerosis (SSc)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Systemic Lupus Erythematosus",
        "Systemic Sclerosis"
      ],
      "interventions": [
        {
          "name": "Reduced Intensity Allogeneic Transplant",
          "type": "PROCEDURE"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Campath",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "New York Medical College",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "7 Years to 50 Years"
      },
      "enrollment_count": 1,
      "start_date": "2007-08",
      "completion_date": "2008-07",
      "has_results": true,
      "last_update_posted_date": "2014-04-01",
      "last_synced_at": "2026-10-21T12:24:10.625Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00684255"
    },
    {
      "nct_id": "NCT06927219",
      "title": "Research Accelerated by You Lupus Registry",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Systemic Lupus Erythematosus (SLE)",
        "Lupus Nephritis (LN)",
        "Cutaneous Lupus Erythematosus (CLE)"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Lupus Foundation of America",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 10000,
      "start_date": "2020-10-01",
      "completion_date": "2050-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-01-23",
      "last_synced_at": "2026-10-21T12:24:10.625Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06927219"
    },
    {
      "nct_id": "NCT06559163",
      "title": "A Study of Obexelimab in Patients With Systemic Lupus Erythematosus",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Systemic Lupus Erythematosus"
      ],
      "interventions": [
        {
          "name": "Obexelimab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Zenas BioPharma (USA), LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 190,
      "start_date": "2024-09-17",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-08-18",
      "last_synced_at": "2026-10-21T12:24:10.625Z",
      "location_count": 32,
      "location_summary": "Peoria, Arizona • Fresno, California • Huntington Park, California + 28 more",
      "locations": [
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Huntington Park",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06559163"
    },
    {
      "nct_id": "NCT01127321",
      "title": "A Safety and Tolerability Study of MEDI-570 in Systemic Lupus Erythematosus",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lupus Erythematosus, Systemic"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "MEDI-570 0.03 MG",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MEDI-570 0.1 MG",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MEDI-570 0.3 MG",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MEDI-570 1 MG",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "MedImmune LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 44,
      "start_date": "2010-05",
      "completion_date": "2012-07",
      "has_results": true,
      "last_update_posted_date": "2014-08-26",
      "last_synced_at": "2026-10-21T12:24:10.625Z",
      "location_count": 9,
      "location_summary": "Long Beach, California • San Leandro, California • Fort Lauderdale, Florida + 6 more",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "San Leandro",
          "state": "California"
        },
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Ocala",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01127321"
    },
    {
      "nct_id": "NCT03285711",
      "title": "Study to Evaluate the Safety and Efficacy of Filgotinib and Lanraplenib in Adults With Lupus Membranous Nephropathy (LMN)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lupus Membranous Nephropathy"
      ],
      "interventions": [
        {
          "name": "Filgotinib",
          "type": "DRUG"
        },
        {
          "name": "Lanraplenib",
          "type": "DRUG"
        },
        {
          "name": "Filgotinib placebo",
          "type": "DRUG"
        },
        {
          "name": "Lanraplenib placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 9,
      "start_date": "2017-10-06",
      "completion_date": "2020-02-03",
      "has_results": true,
      "last_update_posted_date": "2020-05-18",
      "last_synced_at": "2026-10-21T12:24:10.625Z",
      "location_count": 7,
      "location_summary": "Birmingham, Alabama • Palo Alto, California • Gainesville, Florida + 4 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Lawrenceville",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03285711"
    },
    {
      "nct_id": "NCT00611611",
      "title": "BLYS and IFN in SLE",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Systemic Lupus Erythematosus"
      ],
      "interventions": [
        {
          "name": "fluzone",
          "type": "BIOLOGICAL"
        },
        {
          "name": "pneumovax",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "19 Years to 65 Years"
      },
      "enrollment_count": 39,
      "start_date": "2007-10",
      "completion_date": "2009-04",
      "has_results": false,
      "last_update_posted_date": "2011-04-28",
      "last_synced_at": "2026-10-21T12:24:10.625Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00611611"
    },
    {
      "nct_id": "NCT05029336",
      "title": "Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Systemic Lupus Erythematosus",
        "Systemic Sclerosis"
      ],
      "interventions": [
        {
          "name": "Depletion of CD3/CD19 in an autologous stem cell transplant",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Stephan Grupp MD PhD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "8 Years to 25 Years"
      },
      "enrollment_count": 20,
      "start_date": "2026-03",
      "completion_date": "2031-05",
      "has_results": false,
      "last_update_posted_date": "2025-10-14",
      "last_synced_at": "2026-10-21T12:24:10.625Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05029336"
    },
    {
      "nct_id": "NCT03626311",
      "title": "Omega-3 Replacement With Krill Oil in Disease Management of SLE",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Systemic Lupus Erythematosus (SLE)"
      ],
      "interventions": [
        {
          "name": "AKBM-3031",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "OTHER"
      ],
      "sponsor": "Aker BioMarine Human Ingredients AS",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 76,
      "start_date": "2018-10-23",
      "completion_date": "2021-08-21",
      "has_results": false,
      "last_update_posted_date": "2021-10-12",
      "last_synced_at": "2026-10-21T12:24:10.625Z",
      "location_count": 15,
      "location_summary": "Birmingham, Alabama • Beverly Hills, California • Orange, California + 12 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03626311"
    }
  ]
}